MEDP - Medpace Holdings, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

MEDP

MEDPACE HOLDINGS, INC.

NASDAQ

$602.70

▼ DOWN 0.26% (-1.55)

KEY STATISTICS

Market Cap$16.82 B

52w High$677.90

52w Low$373.00

Dividend Yield—

Frequency—

P/E35.33

Volume223.09K

Shares Out.27.91M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

August James Troendle

COMPENSATION 2026

Salary$937,417

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$14,000

Total$11,443,766

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 11, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

6,500

PRICE TARGET

Target High$700.00

Target Low$515.00

Target Median$624.00

Target Consensus$620.44

UPCOMING EARNINGS

DateOct 21, 2026

DayWednesday

Rev. Est.$714.47M

OCT

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

356

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

47.17%

HOLDERS

1,009

TOP 8 OF 1,009 · RANKED BY POSITION SIZE

Price T Rowe Associates Inc /Md/

2.1M sh

$1.1B

Aqr Capital Management LLC

Geode Capital Management, LLC

PRICE

$602.70 ▼ DOWN 0.26% (−$1.55)

About Medpace Holdings, Inc.

https://www.medpace.com ↗

Medpace Holdings, Inc. provides comprehensive clinical research services across all phases for pharma, biotech, and medical device industries worldwide, including development, regulatory, data management, and laboratory support.

INDUSTRY

Medical - Diagnostics & Research

A SERVICE MEDPACE HOLDINGS, INC. IS KNOWN FOR

Full-Service Clinical Research Services

Medpace is a global CRO offering comprehensive clinical development services from Phase I to IV, including study design, patient recruitment, regulatory submissions, and data management for biotech, pharma, and medical device companies.

COMPETITORS

COMPETITOR

Medpace Holdings in 2025

SENTIMENT: + POSITIVE

EARNINGS · JULY 2025

Medpace Stock Soars Over 40% After Smashing Q2 Earnings and Dramatically Raising 2025 Guidance

After issuing conservative guidance that disappointed investors in February 2025, Medpace reported a substantial revenue and earnings beat for the second quarter. The company significantly raised its full-year 2025 revenue and profit forecast, citing lower cancellations and strong business momentum, which triggered a massive surge in its stock price and renewed investor confidence.

CAPITAL ALLOCATION · APRIL 2025 · IN PROGRESS

Medpace Intensifies Shareholder Returns with Aggressive Multi-Billion Dollar Share Repurchase Program in 2025

In 2025, Medpace Holdings, Inc. executed a significant strategic shift in its capital allocation policy by aggressively buying back its own stock. The company repurchased nearly 3 million shares for a total of $912.9 million in the first nine months of the year and, in April, its Board of Directors authorized a $1.0 billion increase to the stock repurchase program.

Latest News

ZACKS INVESTMENT RESEARCH · OCT 6, 2026

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · OCT 5, 2026

Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Argent Capital Management LLC

Argent Capital Management LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ: MEDP) by 5.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 56,996 shares of the company's stock after selling 3,218 shares during the period. Medpace accounts for approximately 0.3% of Argent Capital

READ ARTICLE